Rivaroxaban - McMaster Experts

subject area of

A Replacement for Warfarin Academic Article
A hybrid automated event adjudication system for clinical trials Academic Article
A logical approach to surgical thromboprophylaxis Academic Article
A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment Academic Article
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers Academic Article
A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban Academic Article
A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2) Academic Article
Accumulating data on rivaroxaban for venous thromboembolism in clinical practice Academic Article
Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial Academic Article
Acute management of bleeding in patients on novel oral anticoagulants Academic Article
Advances in Antithrombotic Therapy Academic Article
Advances in the management of venous thromboembolism. Academic Article
Advantages and limitations of the new anticoagulants Academic Article
After PCI with stents for AF, adding rivaroxaban vs warfarin to antiplatelet drugs reduced bleeding Academic Article
An assay to measure levels of factor Xa inhibitors in blood and plasma Academic Article
Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study Academic Article
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors Academic Article
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity Academic Article
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis Academic Article
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? Academic Article
Antiplatelet therapy in the management of atherothrombosis: recent clinical advances Academic Article
Antithrombotic Agents Academic Article
Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making Academic Article
Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent Academic Article
Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source Academic Article
Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Academic Article
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. Academic Article
Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials Academic Article
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty Academic Article
Assays for Measuring Rivaroxaban: Their Suitability and Limitations Academic Article
Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes Academic Article
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials Academic Article
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation Academic Article
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism Academic Article
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism Academic Article
Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source Academic Article
BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study Academic Article
Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach Academic Article
Barriers and facilitators to optimal oral anticoagulant management: a scoping review Academic Article
Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty Academic Article
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin Academic Article
Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness Academic Article
Beyond Unfractionated Heparin and Warfarin Academic Article
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis Academic Article
Bleeding and antidotes in new oral anticoagulants Academic Article
Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study Academic Article
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience Academic Article
Bleeding with direct oral anticoagulants vs warfarin: clinical experience Academic Article
Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design Academic Article
Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment Academic Article
COMPASS for Vascular Surgeons Academic Article
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease Academic Article
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF Academic Article
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source Academic Article
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial Academic Article
Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials Academic Article
Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism Academic Article
Clinical implications of reversal agents for direct oral anticoagulants Academic Article
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications Academic Article
Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure Academic Article
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial Academic Article
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development Academic Article
Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study Academic Article
Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study Academic Article
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events Academic Article
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents Academic Article
Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers Academic Article
Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2) Academic Article
Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation Academic Article
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada Academic Article
Derivation and validation of predictors of oral anticoagulant-related adverse events in seniors transitioning from hospital to home Academic Article
Design of the rivaroxaban for heparin-induced thrombocytopenia study Academic Article
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies Academic Article
Direct oral anticoagulants (DOACs) and pregnancy: A plea for better information Academic Article
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Academic Article
Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review Academic Article
Direct oral anticoagulants: evidence and unresolved issues Academic Article
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence Academic Article
Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances. Academic Article
Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial Academic Article
Effect of extended‐duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis Academic Article
Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism Academic Article
Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi‐database cohort study with meta‐analysis Academic Article
Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state Academic Article
Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism Academic Article
Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism Academic Article
Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1 Academic Article
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants Academic Article
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis Academic Article
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease Academic Article
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD Academic Article
Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty Academic Article
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial Academic Article
Evolving use of new oral anticoagulants for treatment of venous thromboembolism Academic Article
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry Academic Article
External applicability of the COMPASS trial: the Western Denmark Heart Registry Academic Article
Factor Xa and thrombin as targets for new oral anticoagulants Academic Article
Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban Academic Article
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial Academic Article
Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source Academic Article
Functional Abilities of an International Post-Stroke Population: Standard Assessment of Global Everyday Activities (SAGEA) Scale Academic Article
Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies Academic Article
Global Prospective Safety Analysis of Rivaroxaban Academic Article
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease Academic Article
Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis Academic Article
Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy Academic Article
High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source Academic Article
Higher-risk APS: do we dare to DOAC? Academic Article
How I treat heavy menstrual bleeding associated with anticoagulants Academic Article
How I treat target-specific oral anticoagulant–associated bleeding Academic Article
How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland? Academic Article
ISTH guidelines for antithrombotic treatment in COVID‐19 Academic Article
Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban Academic Article
Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE Academic Article
Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy Academic Article
Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study Academic Article
In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days Academic Article
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation Academic Article
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome Academic Article
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants Academic Article
Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy Academic Article
Is there a role for the novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials Academic Article
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants Academic Article
Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation Academic Article
Laboratory measurement of the direct oral anticoagulants Academic Article
Left Atrial Enlargement Could Be Detected on Extended Computed Tomography Angiography Within Initial Stroke Assessment—Reply Academic Article
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin Academic Article
Less menorrhagia for women with VTE Academic Article
Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials Academic Article
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial Academic Article
Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels Academic Article
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials Academic Article
Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS Academic Article
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial Academic Article
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial Academic Article
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease Academic Article
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin Academic Article
Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor Academic Article
Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy Academic Article
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study Academic Article
Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting Academic Article
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source Academic Article
Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent Academic Article
Monitoring and reversal of direct oral anticoagulants Academic Article
Monitoring the anticoagulant effect after a massive rivaroxaban overdose Academic Article
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease Academic Article
Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety? Academic Article
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank Academic Article
New Anticoagulants for Atrial Fibrillation Academic Article
New Anticoagulants for Treatment of Venous Thromboembolism Academic Article
New Anticoagulants for the Prevention of Thromboembolism Academic Article
New Antithrombotic Drugs: Potential for Use in Oncology Academic Article
New oral anticoagulant agents – general features and outcomes in subsets of patients Academic Article
New oral anticoagulants and oculoplastic surgery Academic Article
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions Academic Article
New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty Academic Article
New oral anticoagulants in elderly patients Academic Article
New oral anticoagulants: not quite there yet Academic Article
New oral anticoagulants: which one should my patient use? Academic Article
Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study Academic Article
Novel Oral Anticoagulants: A Focused Review for Stroke Physicians Academic Article
Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism Academic Article
Novel oral anticoagulants in gastroenterology practice Academic Article
Novel oral anticoagulants in secondary prevention of stroke Academic Article
Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants Academic Article
Oral Anticoagulant Therapy Academic Article
Oral Rivaroxaban for Symptomatic Venous Thromboembolism Academic Article
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism Academic Article
Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives Academic Article
Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease Academic Article
Oral factor Xa inhibitors and risk of subdural hematoma Academic Article
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement Academic Article
Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases Academic Article
Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study Academic Article
Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study Academic Article
Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation Academic Article
Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis Academic Article
Overview of the New Oral Anticoagulants Academic Article
Pantoprazole did not reduce risk for a composite of upper gastrointestinal events in stable arterial disease Academic Article
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial Academic Article
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry Academic Article
Patients with Peripheral Artery Disease in the COMPASS Trial Academic Article
Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS ₂ Score: Insights From the BRAIN-AF Trial Academic Article
Perioperative management of patients who are receiving a novel oral anticoagulant Academic Article
Periprocedural Management of Oral Anticoagulation Academic Article
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy Academic Article
Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management Academic Article
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery Academic Article
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients Academic Article
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial Academic Article
Potential Risk Factors Contributing to Development of Venous Thromboembolism for Total Knee Replacements Patients Prophylaxed With Rivaroxaban: A Retrospective Case-Control Study Academic Article
Potential of new anticoagulants in patients with cancer Academic Article
Practical aspects of new oral anticoagulant use in atrial fibrillation Academic Article
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk Academic Article
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban Academic Article
Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study Academic Article
Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study Academic Article
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial Academic Article
Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure Academic Article
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone Academic Article
Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial Academic Article
Procoagulants for management of bleeding with the new oral anticoagulants Academic Article
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study Academic Article
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD) Academic Article
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery Academic Article
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial Academic Article
Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS Academic Article
Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation Academic Article
Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism Academic Article
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD Academic Article
Reply Academic Article
Reply Academic Article
Reply Academic Article
Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban Academic Article
Resident Physicians Choices of Anticoagulation for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation Academic Article
Response to the Letter by Spurling and Colleagues Academic Article
Reversal of Direct Oral Anticoagulants: Current Status and Future Directions Academic Article
Reversal of direct oral anticoagulants: a practical approach Academic Article
Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation Chart Audit) Academic Article
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial Academic Article
Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants Academic Article
Risk of intracranial hemorrhage between different direct oral anticoagulants in older patients seen in the emergency department with a head injury: A population-based cohort study Academic Article
Risk of recurrent venous thromboembolism according to baseline risk factor profiles Academic Article
Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis Academic Article
Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial Academic Article
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial Academic Article
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial Academic Article
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction Academic Article
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease Academic Article
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease Academic Article
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization Academic Article
Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios Academic Article
Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve–Induced Thrombin Generation Academic Article
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization Academic Article
Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro Academic Article
Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial Academic Article
Rivaroxaban and dabigatran did not affect clotting profiles in plasma reconstituted with varying levels of autologous platelets to the same degree as heparin when evaluated using thromboelastography Academic Article
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial Academic Article
Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co‐medication interactions Academic Article
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial Academic Article
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline Academic Article
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source Academic Article
Rivaroxaban for Thromboprophylaxis After Fracture-Related Orthopedic Surgery in Routine Clinical Practice Academic Article
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness Academic Article
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer Academic Article
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older Academic Article
Rivaroxaban for prevention and treatment of venous thromboembolism Academic Article
Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial Academic Article
Rivaroxaban for the prevention and treatment of venous thromboembolism Academic Article
Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease Academic Article
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty Academic Article
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies Academic Article
Rivaroxaban for treatment of HIT: A riveting first experience Academic Article
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation Academic Article
Rivaroxaban for treatment of suspected or confirmed heparin‐induced thrombocytopenia study Academic Article
Rivaroxaban in Orthopedic Surgery — A Change of Paradigm? Academic Article
Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment Academic Article
Rivaroxaban in Peripheral Artery Disease after Revascularization Academic Article
Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation Academic Article
Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation Academic Article
Rivaroxaban in Stable Cardiovascular Disease Academic Article
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits Academic Article
Rivaroxaban in treatment refractory heparin-induced thrombocytopenia Academic Article
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism Academic Article
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial Academic Article
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition Academic Article
Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers Academic Article
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty Academic Article
Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy Academic Article
Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial Academic Article
Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial Academic Article
Rivaroxaban versus enoxaparin after total knee arthroplasty Academic Article
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Academic Article
Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study Academic Article
Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial Academic Article
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease Academic Article
Rivaroxaban with or without aspirin for prevention of cardiovascular disease Academic Article
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial Academic Article
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial Academic Article
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion Academic Article
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease Academic Article
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study Academic Article
Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE) Academic Article
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin Academic Article
Selective factor Xa inhibition for thromboprophylaxis Academic Article
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment Academic Article
Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD Academic Article
Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial Academic Article
Stroke Outcomes in the COMPASS Trial Academic Article
Stroke Prevention in Atrial Fibrillation Academic Article
Stroke and Thromboembolism in Patients with Heart Failure and Sinus Rhythm: A Matter of Risk Stratification? Academic Article
Stroke prevention in atrial fibrillation: Closing the gap Academic Article
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease Academic Article
The COMPASS Trial Academic Article
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population Academic Article
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation Academic Article
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE Academic Article
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations Academic Article
The Optimal Anti-Coagulation for Enhanced-Risk Patients Post–Catheter Ablation for Atrial Fibrillation (OCEAN) trial Academic Article
The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale Academic Article
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement Academic Article
The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study Academic Article
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients Academic Article
The top 4 advances in antithrombotic care in the last year Academic Article
Thromboprophylaxis after knee arthroscopy does not decrease the risk of deep vein thrombosis: a network meta-analysis Academic Article
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials Academic Article
Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding Academic Article
Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies Academic Article
Treatment of venous thromboembolism with dabigatran Academic Article
Trends in Prescribing Oral Anticoagulants in Canada, 2008–2014 Academic Article
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism Academic Article
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study Academic Article
Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review Academic Article
Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study Academic Article
Venous thromboembolism management: where do novel anticoagulants fit? Academic Article
What is the effect of rivaroxaban on routine coagulation tests? Academic Article
XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America Academic Article
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation Academic Article
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation Academic Article
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both Academic Article

Rivaroxaban Concept

Vocabulary Service

Overview

subject area of